Eversept Partners, LP Infla Rx N.V. Transaction History
Eversept Partners, LP
- $993 Million
- Q2 2025
A detailed history of Eversept Partners, LP transactions in Infla Rx N.V. stock. As of the latest transaction made, Eversept Partners, LP holds 1,640,430 shares of IFRX stock, worth $1.36 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
1,640,430
Previous 1,675,978
2.12%
Holding current value
$1.36 Million
Previous $1.71 Million
24.22%
% of portfolio
0.13%
Previous 0.19%
Shares
16 transactions
Others Institutions Holding IFRX
# of Institutions
32Shares Held
17.5MCall Options Held
32.7KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY6.48MShares$5.38 Million0.18% of portfolio
-
683 Capital Management, LLC New York, NY2.48MShares$2.05 Million0.15% of portfolio
-
Ra Capital Management, L.P. Boston, MA1.97MShares$1.64 Million0.03% of portfolio
-
Woodline Partners LP San Francisco, CA751KShares$623,5510.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX705KShares$585,1580.17% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $36.7M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...